Brief: Sio Gene Therapies Announces Positive Interim Safety And Biomarker Data From Ongoing Phase 1/2 Clinical Study Of AXO-AAV-GM1 Gene Therapy In GM1 Gangliosidosis

Sio Gene Therapies

21/10/2021 10:39

Oct 21 (Reuters) - Sio Gene Therapies Inc  SIOX.O :
    * SIO GENE THERAPIES ANNOUNCES POSITIVE INTERIM SAFETY AND
BIOMARKER DATA FROM ONGOING PHASE 1/2 CLINICAL STUDY OF
AXO-AAV-GM1 GENE THERAPY IN GM1 GANGLIOSIDOSIS
    * SIO GENE THERAPIES - AXO-AAV-GM1 GENERALLY WELL-TOLERATED
AT
BOTH LOW AND HIGH DOSES WITH MAJORITY OF ADVERSE EVENTS
CONSIDERED MILD TO MODERATE
    * NO ADVERSE EVENTS LEADING TO STUDY WITHDRAWAL IN ANY
PATIENTS
    * BASED ON RESULTS OF THE STUDY  WORKING ON CONTINUED
DEVELOPMENT
OF AXO-AAV-GM1 AND PLAN TO ENGAGE FDA

Source text for Eikon:  ID:nGNX8MBzDD 
Further company coverage:  SIOX.O 

 ((reuters.briefs@thomsonreuters.com;))